Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab master protocol for chronic pruritus of unknown origin in adults
jRCT2061220017Recruiting
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of dupilumab in chronic idiopathic pruritus (4 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants with at least 4-point reduction in weekly average daily worst itch numerical rating scale from baseline to Week 12. Started May 2022; status: recruiting.
02
Drugs
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on jRCT2061220017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220017.